BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Mar 08, 2010
 |  BioCentury  |  Analyst Picks & Changes

Analyst Picks & Changes

Analyst Picks & Changes

Company Bank Analyst Coverage Opinion Wk chg 3/5 cls
Actelion Ltd. (SIX:ATLN) Jefferies Peter Welford Price target Buy -13% CHF47.80
Welford lowered his target to CHF73 from CHF90 after Tracleer bosentan missed the primary endpoint in the Phase III BUILD-3 trial to treat idiopathic pulmonary fibrosis. Welford still rates the stock a buy, saying the company's pipeline is underappreciated. He expects Phase III data for clazosentan to prevent aneurysmal subarachnoid hemorrhage (aSAH) next half and Phase II data for selexipag to treat pulmonary arterial hypertension (PAH) in May. Clazosentan is an endothelin receptor antagonist and selexipag is a long-acting prostacyclin (IP) receptor (PGI2) agonist (see "Actelion Hasn't Seen Top of PAH," A7).
Adolor Corp. (NASDAQ:ADLR) Wedbush Gregory Wade Upgrade Neutral (from underperform) 21% $1.85
Wade also set a $2 target after the company reported 4Q09 sales of Entereg alvimopan of $4.9M, beating his estimate of $4M, and guided to Entereg sales of $30-$35M in 2010. Adolor co-promotes the selective peripherally acting mu opioid receptor antagonist to treat postoperative ileus (POI) in the U.S. with GlaxoSmithKline plc (LSE:GSK; NYSE:GSK).
Allos Therapeutics Inc. (NASDAQ:ALTH) JMP Securities Charles Duncan Price target ...

Read the full 1231 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >